Bio-Bridge Science Completes Major Construction of Facility to Produce Vaccines and Support Clinical Activities
May 31 2006 - 8:30AM
Business Wire
Bio-Bridge Science, Inc. (OTCBB: BGES), a developer of vaccines
with broad preventative and therapeutic applications, today
announced that it has completed the major construction of a new
state-of-the-art GMP research and manufacturing facility located in
Beijing. The facility will provide a high quality research and
production environment for the Company's vaccine products as well
as pre-clinical and clinical trials. The first phase of the
facility consists of an area 2,200 square meters, which includes
the main facility, where research and production will take place.
The research area consists of an 815 square meter clean air surface
area. This area includes a 470 square meter 100,000 purity grade
clean air environment, and a 345 square meter 10,000 purity grade
clean air environment. There will also be several 100 purity grade
clean air environments within the 10,000 purity grade area. The
facility also includes a 750 square meter general working area and
a 435 square meter electricity and water area. "We are pleased to
have completed the initial stage of development for this
state-of-the-art facility," said Bio-Bridge Science's CEO Dr. Liang
Qiao. "This facility will allow us to produce the first HIV Vaccine
in China, develop additional vaccines to cervical and colon cancers
and to accelerate many of our promising research activities." The
interior and exterior construction was completed according to GMP
rules and requirements; however, construction of the high and low
voltage electricity and installation of steam equipment is still
taking place with local suppliers. About Bio-Bridge Science:
Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine that is
expected to enter clinical trials this year in China. The vaccine,
based on exclusive technology co-developed by CEO Liang Qiao, an
associate professor at Loyola University Chicago's Strich School of
Medicine, targets infection in mucosal tissues, the first type of
tissue attacked by HIV. The Chinese government, mindful of the
rapid expansion of AIDS in China has, through the "Green Mile
Policy", acted to expedite the approval of domestically produced
HIV Vaccines. Bio-Bridge Science's GMP facility will also be used
to develop vaccines against cervical cancer and colon cancer under
the same technology platform as the HIV vaccine. Forward Looking
Statements This press release contains forward-looking statements
as defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government
regulation, and other risks defined in this document and in
statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or
oral, and whether made by or on behalf of the company, are
expressly qualified by these cautionary statements and any other
cautionary statements which may accompany the forward-looking
statements. In addition, the company disclaims any obligation to
update any forward-looking statements to reflect events or
circumstances after the date hereof. Please refer to SEC filings
for additional information and accompanying notes to financial
statements.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024